Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29220935 | 0.93 | GPR119 (0.56) | GPR119DDB1CRBNNAMPTWNT3A | |
| SCHEMBL10180063 | 0.88 | GPR119 (0.59) | GPR119DDB1CRBNNAMPTWNT3A | |
| SCHEMBL21063452 | 0.88 | GPR119 (0.52) | GPR119DDB1CRBNNAMPTWNT3A | |
| SCHEMBL25093627 | 0.87 | DDB1 (0.58) | GPR119DDB1CRBNNAMPTWNT3A | |
| SCHEMBL21607020 | 0.84 | GPR119 (0.58) | GPR119ALDH1A1 | |
| SCHEMBL30263276 | 0.84 | GPR119 (0.58) | GPR119ALDH1A1 | |
| SCHEMBL31706744 | 0.84 | WNT3A (0.51) | GPR119DDB1CRBNNAMPTWNT3A | |
| SCHEMBL64030 | 0.82 | GPR119 (0.53) | GPR119DDB1CRBNALDH1A1MAPT | |
| SCHEMBL28401115 | 0.82 | DDB1 (0.69) | GPR119DDB1CRBNNAMPTWNT3A | |
| SCHEMBL26116390 | 0.82 | GPR119 (0.53) | GPR119DDB1CRBNNAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4543861-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | GPR119 4215/4885DDB1 376/4885CRBN 402/4885 |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | GPR119 447/4885DDB1 2218/4885CRBN 347/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | GPR119 372/4885DDB1 2677/4885CRBN 570/4885 |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | GPR119 53/4885DDB1 1992/4885CRBN 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.